BioWorld

Feb. 5, 2003

View Archived Issues

Invitrogen Buying Technology From Vertex Unit For $95M Cash

Invitrogen Corp. agreed to pay $95 million in cash to purchase certain product lines and technology rights from PanVera LLC, a wholly owned subsidiary of Vertex Pharmaceuticals Inc. (BioWorld Today) Read More

Cell Genesys Cuts Gene Therapy Programs To Focus On Cancer

Read More

MaxCyte, Northern Therapeutics Enter Gene Therapy Delivery Deal

Read More

TransTech Translates Progress Into $24.5M Secured Investment

Read More

Other News To Note

Read More